Case Report
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Jun 27, 2012; 4(6): 196-198
Published online Jun 27, 2012. doi: 10.4254/wjh.v4.i6.196
Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy
Mounia Lahbabi, Nouredine Aqodad, Adil Ibrahimi, Mryem Lahlou, Hafid Aqodad
Mounia Lahbabi, Nouredine Aqodad, Adil Ibrahimi, Department of Hepato-Gastroenterology, Hassan II University Hospital, Fes 30000, Morocco
Mryem Lahlou, Hafid Aqodad, Department of Cardiology, Hassan II University Hospital, Fes 30000, Morocco
Author contributions: Lahbabi M, Aqodad N and Ibrahimi A analyzed and interpreted the patient data regarding the hepatological disease and wrote the manuscript; Lahlou M and Aqodad H were major contributors in writing the manuscript; all authors read and approved the final manuscript.
Correspondence to: Dr. Mounia Lahbabi, Department of Hepato-Gastroenterology, Hassan II University Hospital, Fes 30000, Morocco. m.lahbabi@yahoo.fr
Telephone: +212-67-4225528 Fax: +212-67-4225529
Received: April 6, 2011
Revised: September 4, 2011
Accepted: June 23, 2012
Published online: June 27, 2012
Abstract

Amiodarone chlorhydrate is a diiodated benzofuran derivative used to treat cardiac rhythm abnormalities. Hepatotoxicity is a relatively uncommon side effect of amiodarone and symptomatic hepatic dysfunction occurs in less than 1% to 3% of patients taking amiodarone. We report here on an unusual case of amiodarone-induced hepatotoxicity. A 29 year old woman with normal liver function was given amiodarone intravenously to treat her atrial fibrillation. She developed acute toxic hepatitis after 24 h. The intravenous form of amiodarone was immediately avoided and replaced by the oral form, using conventional loading doses as soon as the deranged liver function tests had normalized, without recurrence of the hepatitis. These observations show that the occurrence of acute hepatic impairment with intravenous amiodarone does not necessarily preclude the use of this drug by mouth and the necessity of monitoring the hepatic function of patients treated with amiodarone.

Keywords: Amiodarone, Hepatitis, Toxic hepatitis, Polyoxenethylated sorbitan ester